Literature DB >> 19617466

CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity.

Sean Hennessy1, Charles E Leonard, Cristin P Freeman, Joshua P Metlay, Xin Chu, Brian L Strom, Warren B Bilker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19617466      PMCID： PMC4339275          DOI： 10.1177/0091270009343006

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  17 in total

1.  Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach.

Authors:  E Yukawa; K Mamiya
Journal:  J Clin Pharm Ther       Date:  2006-06       Impact factor: 2.512

2.  The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.

Authors:  R Kerb; A S Aynacioglu; J Brockmöller; R Schlagenhaufer; S Bauer; T Szekeres; A Hamwi; M Fritzer-Szekeres; C Baumgartner; H Z Ongen; P Güzelbey; I Roots; U Brinkmann
Journal:  Pharmacogenomics J       Date:  2001       Impact factor: 3.550

3.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

Authors:  T H Sullivan-Klose; B I Ghanayem; D A Bell; Z Y Zhang; L S Kaminsky; G M Shenfield; J O Miners; D J Birkett; J A Goldstein
Journal:  Pharmacogenetics       Date:  1996-08

4.  Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.

Authors:  R S Kidd; T B Curry; S Gallagher; T Edeki; J Blaisdell; J A Goldstein
Journal:  Pharmacogenetics       Date:  2001-12

5.  Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.

Authors:  Sarah K Tate; Chantal Depondt; Sanjay M Sisodiya; Gianpiero L Cavalleri; Stephanie Schorge; Nicole Soranzo; Maria Thom; Arjune Sen; Simon D Shorvon; Josemir W Sander; Nicholas W Wood; David B Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-01       Impact factor: 11.205

6.  Medication safety in older adults: home-based practice patterns.

Authors:  Joshua P Metlay; Abigail Cohen; Dan Polsky; Stephen E Kimmel; Ross Koppel; Sean Hennessy
Journal:  J Am Geriatr Soc       Date:  2005-06       Impact factor: 5.562

7.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

Authors:  A H Schinkel; E Wagenaar; C A Mol; L van Deemter
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

8.  Several major antiepileptic drugs are substrates for human P-glycoprotein.

Authors:  Carlos Luna-Tortós; Maren Fedrowitz; Wolfgang Löscher
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

9.  Exploring the possible interaction between anti-epilepsy drugs and multidrug efflux pumps; in vitro observations.

Authors:  Francesca Rivers; Terence J O'Brien; Richard Callaghan
Journal:  Eur J Pharmacol       Date:  2008-09-22       Impact factor: 4.432

10.  MDR1 gene expression in brain of patients with medically intractable epilepsy.

Authors:  D M Tishler; K I Weinberg; D R Hinton; N Barbaro; G M Annett; C Raffel
Journal:  Epilepsia       Date:  1995-01       Impact factor: 5.864
View more
  13 in total

Review 1.  Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists.

Authors:  Victoria M Pratt; Larisa H Cavallari; Andria L Del Tredici; Houda Hachad; Yuan Ji; Ann M Moyer; Stuart A Scott; Michelle Whirl-Carrillo; Karen E Weck
Journal:  J Mol Diagn       Date:  2019-05-08       Impact factor: 5.568

2.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.

Authors:  Ramasamy Kesavan; Sunil K Narayan; Chandrasekaran Adithan
Journal:  Eur J Clin Pharmacol       Date:  2010-07       Impact factor: 2.953

Review 3.  From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics.

Authors:  Bob Wilffert; Jesse Swen; Hans Mulder; Daan Touw; Anke-Hilse Maitland-Van der Zee; Vera Deneer
Journal:  Int J Clin Pharm       Date:  2011-02-11

4.  CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.

Authors:  A Ortega-Vázquez; P Dorado; I Fricke-Galindo; H Jung-Cook; N Monroy-Jaramillo; I E Martínez-Juárez; I Familiar-López; E Peñas-Lledó; A LLerena; M López-López
Journal:  Pharmacogenomics J       Date:  2015-06-30       Impact factor: 3.550

5.  Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

Authors:  K E Caudle; A E Rettie; M Whirl-Carrillo; L H Smith; S Mintzer; M T M Lee; T E Klein; J T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2014-08-06       Impact factor: 6.875

6.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

Review 7.  PharmGKB summary: phenytoin pathway.

Authors:  Caroline F Thorn; Michelle Whirl-Carrillo; J Steven Leeder; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-06       Impact factor: 2.089

Review 8.  From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics.

Authors:  Bob Wilffert; Jesse Swen; Hans Mulder; Daan Touw; Anke-Hilse Maitland-Van der Zee; Vera Deneer
Journal:  Int J Clin Pharm       Date:  2010-11-04

Review 9.  Pharmacogenomic considerations for medications in the perioperative setting.

Authors:  Ellie H Jhun; Jeffrey L Apfelbaum; David M Dickerson; Sajid Shahul; Randall Knoebel; Keith Danahey; Mark J Ratain; Peter H O'Donnell
Journal:  Pharmacogenomics       Date:  2019-07       Impact factor: 2.638

10.  Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects.

Authors:  Natalia Guevara; Cecilia Maldonado; Manuel Uría; Raquel González; Manuel Ibarra; Silvana Alvariza; Antonella Carozzi; Carlos Azambuja; Pietro Fagiolino; Marta Vázquez
Journal:  Pharmaceuticals (Basel)       Date:  2017-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.